Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 18/20 | 0.59 |
| ▸ | CD74 | P04233 | 4/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14107676 | 0.90 | CTSS (0.58) | CTSSCD74 | |
| SCHEMBL2981140 | 0.86 | CTSS (0.55) | CTSSCD74HTR1ADRD2HTR2A | |
| SCHEMBL2985074 | 0.85 | CTSS (0.47) | CTSSHTR1ADRD2HTR2A | |
| SCHEMBL5252008 | 0.83 | HTR2A (0.45) | CTSSHTR1ADRD2HTR2A | |
| SCHEMBL2978841 | 0.83 | CTSS (0.49) | CTSSHTR1ADRD2HTR2A | |
| SCHEMBL2981307 | 0.82 | HTR2A (0.47) | CTSSHTR1ADRD2HTR2A | |
| SCHEMBL5252279 | 0.82 | HTR1A (0.43) | CTSSHTR1ADRD2HTR2A | |
| SCHEMBL2981201 | 0.80 | CTSS (0.61) | CTSSCD74 | |
| SCHEMBL2978847 | 0.78 | CTSS (0.58) | CTSSCD74 | |
| SCHEMBL5529968 | 0.74 | CTSS (1.00) | CTSSCD74 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772236-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2010-08-10 | — | — | US | claimed |
| US-20080293732-A1 | Substituted pyrazoles | BEAVERS MARY PAT | 2008-11-27 | — | — | US | claimed |
| US-7429591-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-09-30 | — | — | US | claimed |
| US-7309703-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2007-12-18 | — | — | US | claimed |
| EP-1309591-B1 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARM INC (US) | 2007-01-24 | — | — | EP | claimed |
| US-20070004747-A1 | Inhibiting the proteolytic activity of cathepsin S; 1-[4-(2-Amino-6-chloro-phenyl)-piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2-ol; antiarthritic agent; autoimmune disease: lupus, rheumatoid arthritis, and asthma | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2007-01-04 | — | — | US | claimed |
| EP-1309591-A2 | SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-14 | — | — | EP | claimed |
| US-20020040020-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-04-04 | — | — | US | claimed |
| WO-2002014314-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | claimed |
| US-7772236-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7589202-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080300255-A1 | Substituted pyrazoles | BEAVERS MARY PAT | 2008-12-04 | — | — | US | disclosed |
| US-20080293732-A1 | Substituted pyrazoles | BEAVERS MARY PAT | 2008-11-27 | — | — | US | disclosed |
| US-7452890-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-20070004738-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004754-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004747-A1 | Inhibiting the proteolytic activity of cathepsin S; 1-[4-(2-Amino-6-chloro-phenyl)-piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2-ol; antiarthritic agent; autoimmune disease: lupus, rheumatoid arthritis, and asthma | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2007-01-04 | — | — | US | disclosed |
| EP-1309591-A2 | SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020040020-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002014314-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293732-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | CTSS 1/4885CD74 80/4885HTR1A 4383/4885 |
| US-20080300255-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | CTSS 1/4885CD74 80/4885HTR1A 4383/4885 |
| US-20070004738-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | CTSS 1/4885CD74 80/4885HTR1A 4383/4885 |
| US-20070004747-A1 | Inhibiting the proteolytic activity of cathepsin S; 1-[4-(2-Amino-6-chloro-phenyl)-piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2-ol; antiarthritic agent; autoimmune disease: lupus, rheumatoid arthritis, and asthma | CTSS, CTSV, CTSZ | CTSS 1/4885CD74 825/4885HTR1A 1721/4885 |
| US-20070004754-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | CTSS 1/4885CD74 80/4885HTR1A 4383/4885 |
| US-20020040020-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | CTSS 1/4885CD74 125/4885HTR1A 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.